Vimian Group AB Company Description

Vimian Group AB (publ) engages in the animal health business worldwide.

It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name.

Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Vimian Group AB (publ)

Country	Sweden
Founded	2020
Industry	Diagnostics & Research
Sector	Healthcare
Employees	1,100
CEO	Patrik Eriksson

Contact Details

Address: Riddargatan 19 Stockholm, 11457 Sweden
Website	vimian.com

Stock Details

Ticker Symbol	VIMIAN
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	SE0015961982
SIC Code	3841

Key Executives

Name	Position
Alireza Tajbakhsh	Head and Chief Executive Officer of VetFamily
Guy C. Sporri	Chief Executive Officer of Movora
Stefano Santarelli	Chief Executive Officer of Indical Bioscience
Magnus Kjellberg	Chief Executive Officer of Nextmune
Patrik Eriksson	Chief Executive Officer
Carl-Johan Zetterberg Boudrie	Chief Financial Officer
Maria Dahllof Tullberg	Head of IR, Communications and Sustainability
Carl-Johan Ehn	General Counsel
Bart Bremer	Chief People Officer
Martin Bengtson	Head of M&A